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Abstract 
Background: The overall survival in Non-Small Cell Lung Cancer (NSCLC) is poor, with 
median overall survival of advanced NSCLC with standard systemic chemotherapy being 
reported at 13.6 months and the 5-year survival rate was less than 15%. Therefore, the aim of 
this study was to evaluate the endostar combined with chemotherapy in patients with advanced 
NSCLC. Methods: 116 cases of the histological pathology diagnosed stage IIIB-IV NSCLC 
were retrospectively collected. The control group was treated with chemotherapy combined 
with intravenous infusion of Endostar while the test group was durative transfusion of Endostar. 
The short-term therapeutic effects including overall response rate (ORR), disease control rate 
(DCR) and safety were evaluated in the both groups. In the follow-up, progressive free survival 
(PFS) and overall survival (OS) were also analysed. Results: In the test group, the ORR is 
53.4%, which is similar to the control group (44.8%) (p>0.05). However, the DCR in the test 
group (86.2%) is significantly higher than the control group (70.7%) (p<0.01). The median 
time to progression in the test group (6 months) is also significantly longer than the control 
group (4 months). Importantly, the median OS in the test group (17.5 months) was improved 
compared to the control group (13.5 months). The one-year survival rate in the test and control 
groups was 9.7% and 15.8%. There was no significant difference in the side effects including 
thrombocytopenia, leucopenia，nausea and vomiting between the two groups. Conclusions: 
Endostar durative transfusion combined with chemotherapy showed a higher DCR, longer PFS, 
OS time and well tolerated in patients with advanced NSCLC. 
 
 
Background  
Lung cancer is the most common malignancy and cause of cancer-related deaths worldwide, 
particularly non-small cell lung cancer (NSCLC). This may be due to approximately 57% of 
all lung cancers being found at an advanced stage at diagnosis 1,2. The accepted standard duel 
regimen chemotherapy consisting of paclitaxel and a platinum agent which demonstrates 
consistent objective responses 3. However, the 5-year survival rate is still low 4 and treatment 
efficacy needs to be improved.  
 
Solid tumour growth requires both nutrients and oxygen, which is facilitated by vessel 
angiogenesis to enable energetic tumour cell proliferation 5. Therefore, anti-angiogenesis has 
represented a new approach for targeted cancer therapy 6. Recent, clinical studies have 
demonstrated patients with advanced non-small cell lung cancers (NSCLCs) benefitting further 
from anti-angiogenic therapy, when combined with chemotherapeutic regimes 7, 8. 
 
Endostatin is an endogenous angiogenesis inhibitor with strong anti-angiogenic activity that 
can inhibit the growth of various tumours and prevent the progression of metastasis 9. Endostar, 
a novel recombinant human endostatin with an additional nine-amino acid sequence 
(MGGSHHHHH) at the N terminus, increased heat stability and proteolytic resistance 
compared to endogenous endostatin 10. It has been reported that Endostar, as an angiogenesis 
inhibitor, strongly inhibits the growth of a variety of murine and xenotransplanted human 
tumours 11. The clinical studies show that Endostar combined with first-line chemotherapy 
(vinorelbine-cisplatin or paclitaxel-carboplatin) in patients with advanced NSCLC 
significantly improved the progression-free survival (PFS) time and overall survival (OS) time 
12.  
 
Endostar is recommended to be administered by intravenous infusion once per day for four 
hours, nevertheless, its half-life in vivo is only 10 h, and thus the efficacy of endostar is limited. 
The mini-osmotic pump is a modality of delivering a continuous infusion, which is able to 
deliver a variety of solutions or suspensions at a constant rate for days and even up to several 
weeks. Thereby enabling an effective concentration of drug to be maintained and the efficacy 
of the drug enhanced. Here, we investigated whether the durative transfusion of Endostar 
combined with chemotherapy could enhance the efficacy in advanced NSCLC compared to 
intravenous infusion once a day combined with chemotherapy for 10 days. 
 
Materials and Methods  
 
Eligibility/Inclusion Criteria 
 
A retrospective review of all consecutive patients with pathologically confirmed stage IIIB-IV 
NSCLC were collected and analysed, over five- year period. These patients were staged 
according to American Joint Committee on Cancer Staging System. All patients were required 
to have at least one measurable tumour, which was not amenable to surgical excision. Further 
eligibility criteria required patients older than 18-years, the Karnofsky performance status 
(KPS) is more than 70 points, and life expectancy being greater than three-months. Finally, all 
patients’ blood routine, liver and kidney function, and electrocardiogram (ECG) were identified 
as normal before the trial.  
 
Patients were split into two groups where patients undergoing standard intravenous 
chemotherapy were defined as the control group and patients undergoing treatment durative 
pump chemotherapy, were defined as the treatment group. 
 
Due to the nature of a retrospective review of approved treatment regimens, which were not 
experimental trials, submission and approval to a formal ethics committee was not required.  
 
Therapy schedule  
The control group received intravenous infusion of Endostar once per day combined with 
chemotherapy, whilst the test group was treated with durative transfusion of Endostar for 10 
days in each chemotherapy cycle. The chemotherapeutics for both groups were mainly 
docetaxel, gemcitabine, Pemetrexed, cisplatin and Nedaplatin. For the intravenous infusion, 
Endostar was given daily at the dose of 15 mg in 500 ml saline for 4 hours from day 1 to day 
14 and repeated 7 days later. For the durative transfusion, Endostar was continuously pumped 
at the rate of 5 ml/h (210 mg in 279 ml saline) by the mini-osmotic pump (DBB-I-I type, Love's 
scientific instrument co., LTD, China) from day 1 to day 10.  
 During administration of Endostar, patient heart rate, blood pressure, pulse oxygen saturation 
and electrocardiogram were continuously monitored using an intelliVue MP20 patient monitor 
(Royal Philips Electronics, the Netherlands).  
 
Evaluation of efficacy  
The clinical symptoms and signs, side effects, and blood routine were examined every week. 
Blood chemistry and ECG were performed in every cycle. Efﬁcacy was evaluated by CT scan 
in each cycle according to the Response Evaluation Criteria in Solid Tumours (RECIST) 
including complete response (CR), partial response (PR), stable disease (SD), and progressive 
disease (PD). The disease control rate (DCR) was defined as the percentage of patients with 
CR, PR or SD. The overall response rate (ORR) was defined as the percentage of patients with 
CR or PR. OS was defined as the time from first treatment to death while PFS was considered 
as the time from randomization to tumour progression or death from any cause. 
 
Statistical analysis  
Statistical analysis was performed using the SPSS 18.0 statistical package. The short-term 
efficacy between the two groups were analysed by χ2 test. The differences in KPS were 
analysed by t test. Survival curves were drawn by Kaplan-meier method using the GraphPad 
prism software. Log-rank test was used to compare the survival rates of the two groups. A value 
of p < 0.05 was considered to be statistically significant.  
 
Results 
Patient characteristics 
A total of 116 patients were enrolled in the study, with an even split of 58 patients in both the 
control and treatment group. Characteristics of patients were summarized in Table 1. Of the 
control group there were 37 males and 21 females. The age range was 45- 70 years. Whereas, 
the treatment group consisted of 40 male and 18 female patients. The age range was 41-67years. 
There was no statistically significant difference in age, gender, clinical stage, smoking status, 
Karnofsky performance status, epidermal growth factor receptor (EGFR) status and Histology 
between the two groups. 
 
Response to therapy   
Following treatment, we observed that the control group had 1 case of CR, 13 cases of PR and 
16 cases of SD. The test group had 0 case of CR, 22 cases of PR and 14 cases of SD. The 
overall response rate (CR+PR) between the two groups was similar. However, the DCR of the 
test group was significantly improved, when compared to the control group (Table 2) (p<0.01). 
Importantly, the median PFS was significantly improved from 4 months in the control group, 
to 6 months in the test group (p=0.037) (Fig. 1a). The median OS time was also seen to be 
extended from 13.5 months in the control group to 17.5 months in the test group (p=0.034) 
(Fig. 1b). Finally, the one-year survival rate of the test group and the control group was seen to 
be 9.7% and 15.8%, respectively.  
 
Safety  
Patients were carefully monitored for significant, unintended and unwanted side effects. Mild 
to moderate side effects such as fatigue, vomiting, diarrhoea, and myelosuppression were 
tolerated well by all patients (Table 3). There were no significant differences in the side effects 
between the two groups. Only one case in the test group had grade IV myelosuppression and 
recovered after the injection of recombinant human granulocyte colony-stimulating factor and 
recombinant human interleukin-11. There were no treatment-related deaths. 
 
Discussion  
In the treatment of non-small cell lung cancer, the efficacy of first-line platinum-containing 
regimen of duel regimen therapy has reached a bottleneck. The addition of anti-angiogenic 
drugs can improve efficacy and prolong survival. These have been confirmed previously by 
ECOG4599 and Beyond clinical trials. Endostar is a vascular endothelial inhibitor, which was 
developed by China independently and its mechanism is different from bevacizumab (anti-
VEGF receptor monoclonal antibody). 
 
Phase IV clinical trials showed that applying Endostar both in first-line and second-line 
chemotherapy in the treatment of non-small cell lung cancer could increase ORR and 1-year 
survival rate13. Therefore, this study changes the mode of administration, using a continuous 
infusion method, to maintain a stable blood concentration. Compared to traditional 
intravenous infusion for four hours per day, the continuous infusion mode is safer and can 
improve patients’ compliance, shorten the time in hospital and cut costs. 
 
Previously, a number of studies have demonstrated the Endostar can maintain the stability of 
physical and chemical properties under normal conditions at high concentration in vitro. 
    
Endostatin, an endogenous angiogenic inhibitor, has been shown to inhibit VEGF, 
metalloproteinases, integrins, c-myc, cyclin D1, and even the Wnt signaling pathway 14. In 
vitro, Endostar (the recombination human endostatin) can inhibit the growth of human lung 
adenocarcinoma cell line SPC-A4, the migration of human umbilical vein endothelial cell 
(HUVEC), and the angiogenesis of Chorio Allantioc Membrane 15. Furthermore, Endostar 
can suppress tumour growth in mouse models (S180 sarcoma, H22 liver cancer) and human 
xenograft models (SPC-A4 lung adenocarcinoma, SGC7901 gastric cancer, HeLa cervical 
cancer, SMMC-7721 and Bel7402 liver cancer). It has been reported that Endostar can 
suppress not only the angiogenesis but also lymph node metastasis 16,17. The addition of 
Endostar results in significant improvement in RR, median time to tumour progression, and 
clinical benefit rate in patients with advanced NSCLC 12,18- 20. From 2007, Endostar could be 
used as a first line agent together with chemotherapy in the treatment of NSCLC 21. No death 
related to Endostar has been reported. In I ~ III period clinical study, heart reaction is the 
main adverse event in dose limited toxicity of Endostar and arrhythmia is the most common 
case 22, 23.  
 
Our results showed that the durative transfusion of Endostar significantly improved the DCR 
and PFS compared to the intravenous infusion, although the ORR had no significant 
difference between the two groups. Importantly, the OS in test group was significantly 
extended compared to the control group. Within the literature, a randomized, double-blind, 
placebo-controlled study demonstrated that Endostar plus chemotherapy caused only grade 1 
and grade 2 cardiac ischemia in patients, but no significant difference was noted in OS and 
PFS between the treatment and control groups 24. The different timing, sequence or dose of 
the anti-angiogenic drugs in combination with cytotoxic chemotherapy drugs might be 
resulted in the distinct clinical efficacy, but we thought that the different injection methods 
might be the major reason. The mini-osmotic pump was used to do the durative transfusion of 
Endostar in our study, which can maintain stable and effective blood drug concentration. 
Therefore, the efficacy of Endostar was improved. Furthermore, manageable side effects 
were observed in our study and there was no significant difference in the two groups. 
Previously, in a determination of Endostar concentration test, to exclude the effects of 
residual drug released from the osmotic pump 24 h after termination of pump flow, the 
concentrations of Endostar in serum of the control and test groups were tested at that time 
point, only nanogram amounts of drug were detected in the serum of the two groups and there 
was no difference, indicating that the difference between the two groups was not due to the 
residual Endostar in the pump 25. 
 
In conclusion, the continuous administration of Endostar combined with chemotherapy for 
advanced NSCLC results in a higher DCR and longer PFS, with tolerable adverse effects. 
Further work would include prospective randomisation studies to further evaluate treatment 
response. 
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Table 1. Baseline characteristics of the patients 
 
Table 2 Comparison of efficacy between control group and test group  
Response evaluation  Control group (%) Test group (%)     P 
CR 1(1.7) 0(0) >0.05 
PR 25(43.1) 31(53.4) >0.05 
SD 15(25.9) 19(32.8) >0.05 
ORR 26(44.8) 31(53.4) >0.05 
DCR 41(70.7) 50(86.2) <0.01 
 
 
 
 
 
 
Characteristic Control group (n=58, %) 
Intravenous infusion 
Test group (n=58, %)  
Durative transfusion 
χ2 P 
Number of case 58(50.0) 58(50.0)   
sex     
female 21 18 0.56 
 
0.41 
male 37 40  
Age range 45-70 41-67   
   median age 60 57   
Clinical stage     
IIIB 
IV 
15 
43 
19 
39 
1.18 0.28 
Smoking status     
   Never smoker 30 32 0.38 0.67 
    Current smoker 28 26   
Karnofsky     
70-80 
80-90 
4 
54 
5 
53 
0.47 0.31 
EGFR status     
  M(+) 18 20 0.29 0.79 
  M(-) 22 22   
  NE 18 16   
Histology     
Adenocarcinoma 14 24 0.77 0.68 
Squamous cell carcinoma 22 22   
Large cell Undifferentiated 
carcinoma 
1 0   
Table 3 Comparison of adverse reactions between two groups (n = 116) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxicity   Control group Test group  
 Ⅰ~Ⅱ Ⅲ~Ⅳ  Ⅰ~Ⅱ Ⅲ~Ⅳ        P value 
Neutropenia 30 16 30 17              0.963 
anemia 16 2 19 2               0.904 
thrombocytopenia 9 1 9 1               0.999 
hemorrhage 0 0 0 0               1.000 
Nausea/vomiting 31 4 29 5               0.980 
mucositis 0 0 1 0               0.422 
diarrhea 3 1 2 0               0.553 
constipation 13 1 10 0               0.822 
Transaminase increase 3 0 4 0               0.860 
Total bilirubin increase 0 0 1 0               0.423 
Serum creatine increase 0 0 0 0               1.000 
Fever 0 0 1 0               0.423 
Skin rash 1 0 0 0               0.423 
Fatiaue 21 1 19 2               0.973 
Pain 6 1 7 0               0.999 
Allergy 0 0 1 0               0.423 
Peripheral nerve toxicity 2 0 1 0               0.698 
Alopecia 8 1 7 0               0.858 
Arrhythniia 2 0 4 0               0.698 
  
